HYEX · Healthy Extracts Inc.
$1.24
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to its neutral cash flow, the Company has doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, most of the Company's development activities since inception have been financially sustained through equity financing but it is using all additional cash flow to help support the Company's growth and research and development of new products. Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entity's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$17.25M
Shares
14.74M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$4.51M
+44.9%
FY2025
Net Income
-$881.12K
-4.8%
FY2025
Gross Margin
53.69%
-7.7pp
FY2025
Operating Margin
-4950.41%
+42961.3pp
FY2018
Operating Cash Flow
$165.52K
-41.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.29M | $4.51M | $3.11M | $2.49M | $2.25M | $1.68M | $1.3M | $748.38K | $67.13K | $7605 | $162.75K | $115.55K | |
| -$338K | -$210.28K | -$186.25K | -$176.95K | -$64.69K | -$52.45K | -$72.88K | -$87.48K | -$1.27M | -$2.64M | -$1.07M | $61 | |
| $2.44M | $2.09M | $1.2M | $864.06K | $879.95K | $981.52K | $1.86M | $524.49K | $28.59K | $4761 | $26.93K | $46.63K | |
| $3.85M | $2.42M | $1.91M | $1.62M | $1.37M | $695.08K | -$578.44K | $223.88K | $38.54K | $2844 | $135.82K | — | |
| — | 53.69% | 61.39% | 65.24% | 60.92% | 41.46% | -44.52% | 29.92% | 57.41% | 37.4% | 83.45% | — | |
| $4.95M | $3.37M | $2.09M | $3.87M | $2.28M | $2.58M | $1.47M | $1.16M | $306.94K | $538.7K | $758.43K | $386.6K | |
| — | — | — | — | — | — | $1.58M | — | — | — | — | — | |
| — | — | — | — | — | $5100 | $9048 | $8527 | $8332 | $3094 | $1329 | $1588 | |
| $4.95M | $3.37M | $2.09M | $3.87M | $2.28M | $2.58M | $3.05M | $1.16M | $546.03K | $951.92K | $961.58K | $846.48K | |
| — | — | — | — | — | — | — | — | -$3.32M | -$3.64M | -$825.76K | -$730.93K | |
| — | — | — | — | — | — | — | — | -4950.41% | -47911.74% | -507.38% | -632.56% | |
| — | — | — | — | — | — | — | — | -$3.31M | -$3.64M | -$824.43K | -$729.35K | |
| $227.5K | $62.73K | -$657.52K | -$229.09K | -$71.53K | -$97.95K | — | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| -$879.36K | -$881.12K | -$840.67K | -$2.47M | -$983.12K | -$1.99M | -$2.58M | $632.78K | -$3.33M | -$3.56M | -$3.37M | -$730.87K | |
| — | -19.53% | -27% | -99.48% | -43.67% | -118.52% | -198.27% | 84.55% | -4959.73% | -46838.59% | -2071.24% | -632.51% | |
| shares | — | — | — | — | — | — | 1.98M | 921.77K | 22.9K | 1876.75 | 130.71K | 117.78K |
| shares | — | — | — | — | — | — | 1.98M | 921.77K | 22.9K | 1876.75 | 130.71K | 117.78K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 54 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.11×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 33 similar-size Drug Manufacturers - Specialty & Generic companies (of 95 listed).